Accelerating Pulmonary Fibrosis Therapy Development

	Respiratory Diseases
	The latest respiratory diseases news from News Medical

Pulmonary fibrosis remains a complex therapeutic challenge, demanding earlier insight, stronger translational models, and smarter clinical strategies. This eBook explores how emerging science and development approaches are helping teams accelerate next-generation therapies, improve evidence generation, and address unmet needs for patients living with progressive fibrotic lung disease worldwide today successfully.

Download the eBook

			Protein-based MRI agent detects tiny lung cancer metastases A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

			Researchers find greater microplastic burden in lung cancer patients People with lung cancer are more likely to have microplastics in their lungs and to have larger quantities of microplastics in their lungs, according to research that will be presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

	Study shows how the microbiome shapes lung cancer immunotherapy outcomes Despite the revolutionary impact of immune checkpoint inhibitors on cancer therapy, 60% to 80% of patients with NSCLC still show suboptimal responses.

	Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

	Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

	Catheter-directed thrombolysis improves short-term outcomes in pulmonary embolism patients In patients with intermediate−high risk pulmonary embolism, catheter-directed thrombolysis improved short-term clinical outcomes compared with standard anticoagulation therapy alone, according to results presented in a Hot Line session today at ESC Congress 2026.

How would you rate today's newsletter?

Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2026